JP Morgan Chase
RVMD icon

JP Morgan Chase’s Revolution Medicines RVMD Stock Holding History

JP Morgan Chase’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9M Buy
+128,000
New +$12.9M ﹤0.01% 2523
2025
Q1 		– Sell
-3,200
Closed -$140K – 7670
2024
Q4 		$140K Sell
3,200
-53,900
-94% -$2.72M ﹤0.01% 5625
2024
Q3 		$2.59M Buy
57,100
+53,900
+1,684% +$2.35M ﹤0.01% 3788
2024
Q2 		$124K Buy
+3,200
New +$120K ﹤0.01% 5410
2023
Q4 		– Sell
-135,000
Closed -$3.74M – 7829
2023
Q3 		$3.74M Buy
+135,000
New +$4M ﹤0.01% 3054

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase's RVMD Position: Q1 2026 in Review

JP Morgan Chase reduced its Revolution Medicines (RVMD) stake by 29% in Q1 2026, selling an estimated $12.1M and leaving 301,393 shares worth $27.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1801.

JP Morgan Chase first reported a position in RVMD in Q1 2020 and has held it in 25 quarters since. The position peaked at $188M in Q3 2024. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • JP Morgan Chase held 301,393 shares of Revolution Medicines worth $27.9M as of Q1 2026.
  • JP Morgan Chase sold 120,234 Revolution Medicines shares in Q1 2026, an estimated $12.1M.
  • Revolution Medicines made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1801 holding.
  • JP Morgan Chase first reported a position in Revolution Medicines in Q1 2020 and has held it in 25 quarters since.
  • JP Morgan Chase's Revolution Medicines position peaked at $188M in Q3 2024.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.